Vanda Pharmaceuticals Inc.
VNDA
$5.04
$0.122.44%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 17.48% | 22.76% | 9.59% | -24.06% | -29.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.48% | 22.76% | 9.59% | -24.06% | -29.79% |
| Cost of Revenue | -25.14% | -16.72% | -21.89% | -27.94% | -44.53% |
| Gross Profit | 21.01% | 26.15% | 12.18% | -23.74% | -28.21% |
| SG&A Expenses | 66.36% | 51.71% | 39.00% | -16.67% | -27.97% |
| Depreciation & Amortization | 83.84% | 360.79% | 363.49% | 432.45% | 151.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.20% | 30.89% | 23.91% | -6.28% | -9.49% |
| Operating Income | -44.90% | -83.49% | -253.89% | -560.83% | -207.01% |
| Income Before Tax | -291.15% | -5,103.33% | -312.81% | -184.37% | -117.28% |
| Income Tax Expenses | -314.48% | -257.98% | -193.10% | -122.76% | -73.15% |
| Earnings from Continuing Operations | -104.67% | -3,986.13% | -397.24% | -227.49% | -134.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.67% | -3,986.13% | -397.24% | -227.49% | -134.98% |
| EBIT | -44.90% | -83.49% | -253.89% | -560.83% | -207.01% |
| EBITDA | -39.93% | -66.81% | -261.06% | -362.19% | -181.40% |
| EPS Basic | -101.92% | -3,908.33% | -392.83% | -225.96% | -134.43% |
| Normalized Basic EPS | -27.29% | -5,053.85% | -309.93% | -183.33% | -254.77% |
| EPS Diluted | -80.00% | -3,908.33% | -401.89% | -225.96% | -141.84% |
| Normalized Diluted EPS | -27.29% | -5,053.85% | -309.93% | -183.89% | -256.26% |
| Average Basic Shares Outstanding | 1.35% | 1.29% | 1.33% | 1.31% | 1.55% |
| Average Diluted Shares Outstanding | 1.35% | 1.16% | 1.19% | 0.63% | 0.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
